Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2143381 | 0.87 | ADORA2A (0.30) | ADORA2A | |
| SCHEMBL5951884 | 0.79 | DGAT1 (0.38) | DGAT1BRD4CREBBPNPC1 | |
| SCHEMBL112535 | 0.78 | NPC1 (0.34) | DGAT1BRD4CREBBPNPC1 | |
| SCHEMBL4069249 | 0.78 | SMN1; SMN2 (0.35) | DGAT1BRD4CREBBPNPC1 | |
| SCHEMBL21458046 | 0.78 | DGAT1 (0.37) | DGAT1BRD4CREBBPNPC1ADORA2A | |
| SCHEMBL23122502 | 0.78 | ADA (0.36) | DGAT1BRD4CREBBPNPC1 | |
| SCHEMBL15825447 | 0.78 | DGAT1 (0.40) | DGAT1BRD4CREBBPNPC1 | |
| SCHEMBL29117073 | 0.77 | BRD4 (0.39) | DGAT1BRD4CREBBPNPC1 | |
| SCHEMBL22717563 | 0.76 | NPC1 (0.37) | DGAT1BRD4CREBBPNPC1ADORA2A | |
| SCHEMBL23123000 | 0.76 | NPC1 (0.35) | DGAT1BRD4CREBBPNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424843-B1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | NOVARTIS AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| US-20120101064-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101064-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | CDK3, CCNI, CDK1 | DGAT1 4775/4885BRD4 610/4885CREBBP 1826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.